Human Peripheral Blood Mononuclear Cells (PBMCs) are blood cells with a single round nucleus. These cells include lymphocytes (T, B and NK cells), monocytes and dendritic cells.  PBMCs are parts of the immune system which are critical to cell-mediated and humoral immunity.

Our Human PBMCs are isolated from normal healthy donor leukopaks collected in acid-citrate-dextrose formula A (ACDA) as an anticoagulant. All donors must be tested negative for HBV, HCV, HIV and Syphilis and are IRB consented.

Peripheral blood mononuclear cells (PBMCs) are purified by a density gradient centrifugation (Ficoll-Paque) and are available in fresh and frozen (cryopreserved) format.  HumanCells' PBMC are isolated from Leuko Pak (Apheresis-derived) which are highly purified, containing a more pure population of mononuclear cells with higher viability when compared to buffy coat derived cells.

Storage Condition

Cryopreserved PBMCs can be stored in Liquid Nitrogen vapor phase for long-term storage.  Storage in liquid phase nitrogen is NOT recommended. Short-term storage of cells (less than 2 weeks) at -80°C is acceptable but should be minimized to ensure maximum stability. Once thawed, samples must be used immediately, and can not be frozen again.

Also available from  

Fisher Catalog No.:  

• NC1681388 (Frozen, 10 million, Cat#: PBMC-C10M)
• NC1814842 (Frozen, 20 million, Cat#: PBMC-C20M)
• NC2110997 (Fresh, 50 million, Cat#: PBMC-F50M)
• NC1814844 (Frozen, 100 million, Cat#: PBMC-C100M)
• NC2101392 (Fresh, 100 million, Cat#: PBMC-F100M)
• NC2101862 (Fresh, 300 million, Cat#: PBMC-F300M)
• NC2101863 (Fresh, 500 million, Cat#: PBMC-F500M)
• NC2101866 (Fresh, 2 billion, Cat#: PBMC-F2B)
• NC2101868 (Fresh, 4 billion, Cat#: PBMC-F4B)

Our pooled donor PBMC (Mix donor PBMC) were pooled from 2-5 donors. For specific requirement, please contact us at [email protected]

Product Citation:

• Wu, Kerui, et al. "Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence." Science Advances 9.17 (2023): eade0625. https://www.science.org/doi/10.1126/sciadv.ade0625
• Mao, Chengqiong, et al. "Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression." Science translational medicine 14.648 (2022):DOI:10.1126/scitranslmed.abh1261